https://www.selleckchem.com/pr....oducts/2-3-butanedio
BACKGROUND Pharmacodynamic and pathophysiologic changes in critically ill adults receiving cefepime may increase the risk of adverse events. This study evaluated the impact of cefepime exposure on neurotoxicity development in critically ill adults with renal dysfunction. METHODS Critically ill adults with creatinine clearance less then 60 mL/min who received cefepime for ≥48 hours between 1 January 2014 and 31 July 2018 were evaluated for cefepime-associated neurotoxicity (CAN) development. Higher- and lower-dose cefe
Like
Comment
Share
